Stock Research for ABIO

ABIO

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ABIO Stock Chart & Research Data

The ABIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABIO Due diligence Resources & Stock Charts

The ABIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABIO Detailed Price Forecast - CNN Money CNN View ABIO Detailed Summary - Google Finance
Yahoo View ABIO Detailed Summary - Yahoo! Finance Zacks View ABIO Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ABIO Trends & Analysis - Trade-Ideas Barrons View ABIO Major Holders - Barrons
NASDAQ View ABIO Call Transcripts - NASDAQ Seeking View ABIO Breaking News & Analysis - Seeking Alpha
Spotlight View ABIO Annual Report - CompanySpotlight.com OTC Report View ABIO OTC Short Report - OTCShortReport.com
TradeKing View ABIO Fundamentals - TradeKing Charts View ABIO SEC Filings - Bar Chart
WSJ View Historical Prices for ABIO - The WSJ Morningstar View Performance/Total Return for ABIO - Morningstar
MarketWatch View the Analyst Estimates for ABIO - MarketWatch CNBC View the Earnings History for ABIO - CNBC
StockMarketWatch View the ABIO Earnings - StockMarketWatch MacroAxis View ABIO Buy or Sell Recommendations - MacroAxis
Bullish View the ABIO Bullish Patterns - American Bulls Short Pains View ABIO Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ABIO Stock Mentions - StockTwits PennyStocks View ABIO Stock Mentions - PennyStockTweets
Twitter View ABIO Stock Mentions - Twitter Invest Hub View ABIO Investment Forum News - Investor Hub
Yahoo View ABIO Stock Mentions - Yahoo! Message Board Seeking Alpha View ABIO Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ABIO - SECform4.com Insider Cow View Insider Transactions for ABIO - Insider Cow
CNBC View ABIO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABIO - OTC Markets
Yahoo View Insider Transactions for ABIO - Yahoo! Finance NASDAQ View Institutional Holdings for ABIO - NASDAQ


Stock Charts

FinViz View ABIO Stock Insight & Charts - FinViz.com StockCharts View ABIO Investment Charts - StockCharts.com
BarChart View ABIO Stock Overview & Charts - BarChart Trading View View ABIO User Generated Charts - Trading View




Latest Financial News for ABIO


Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks
Posted on Tuesday June 19, 2018

Research coverage has been initiated by WallStEquities.com on Aimmune Therapeutics Inc. (NASDAQ: AIMT), Alkermes PLC (NASDAQ: ALKS), Aratana Therapeutics Inc. (NASDAQ: PETX), and ARCA biopharma Inc. (NASDAQ: ABIO). The majority of Biotech companies research and develop products for the healthcare market.


GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress
Posted on Tuesday May 29, 2018

ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that data from the GENETIC-AF clinical trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European Society of Cardiology Heart Failure 2018 World Congress on Sunday May 27, 2018.  William T. Abraham, M.D., Professor of Medicine, Physiology and Cell Biology and Director, Division of Cardiovascular Medicine at the Ohio State University presented the data.  The presentation is available at http://arcabio.com/investors/investor-presentations/. In the overall study population of heart failure patients who were at high risk for recurrent atrial fibrillation (AF), pharmacogenetic guided GencaroTM did not reduce AF/AFL/ACM recurrence compared to the active comparator TOPROL-XL.


Today’s Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma
Posted on Friday May 11, 2018

NEW YORK, NY / ACCESSWIRE / May 11, 2018 / vTv Therapeutics and ARCA biopharma were both soaring in Thursday's trading session. Both had news as catalysts to drive shares higher with vTv Therapeutics announcing ...


ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress
Posted on Thursday May 10, 2018

ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that data from the Phase 2B GENETIC-AF clinical trial has been selected for a “Late Breaking Clinical Trials” oral presentation at the European Society of Cardiology Heart Failure 2018 World Congress being held May 26-29, 2018 in Vienna, Austria.  William T. Abraham, M.D., Professor of Medicine, Physiology and Cell Biology and Director, Division of Cardiovascular Medicine at the Ohio State University will present the data.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.